{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:00:42Z","timestamp":1761663642990,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T00:00:00Z","timestamp":1498262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"PUMC Youth Fund and the Fundamental Research Funds for the Central Universities","award":["2017320028"],"award-info":[{"award-number":["2017320028"]}]},{"DOI":"10.13039\/501100001809","name":"The Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81501807"],"award-info":[{"award-number":["81501807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Outstanding Talents Cultivation Program","award":["2015000020124G071"],"award-info":[{"award-number":["2015000020124G071"]}]},{"name":"ZheJiang Hisun Pharmaceutical Co., LTD"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jmii.2017.06.007","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T15:58:53Z","timestamp":1498751933000},"page":"411-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["High in\u00a0vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China"],"prefix":"10.1016","volume":"51","author":[{"given":"Jing-Wei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Lan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kudinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanrong","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Wei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2017.06.007_bib1","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMra0707500","article-title":"Clostridium difficile\u2013more difficult than ever","volume":"359","author":"Kelly","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2017.06.007_bib2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrmicro2164","article-title":"Clostridium difficile infection: new developments in epidemiology and pathogenesis","volume":"7","author":"Rupnik","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ng.2478","article-title":"Emergence and global spread of epidemic healthcare-associated Clostridium difficile","volume":"45","author":"He","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.jmii.2017.06.007_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2047-2994-2-21","article-title":"Epidemiology of Clostridium difficile infection in Asia","volume":"2","author":"Collins","year":"2013","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jmii.2017.06.007_bib5","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3389\/fmicb.2016.01621","article-title":"Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from a university teaching hospital in China","volume":"7","author":"Cheng","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib6","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ijantimicag.2016.09.009","article-title":"Toxin profiles, PCR ribotypes and resistance patterns of Clostridium difficile: a multicentre study in China, 2012-2013","volume":"48","author":"Gao","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2017.06.007_bib7","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1128\/JCM.00587-13","article-title":"Molecular epidemiology of Clostridium difficile infection in a major Chinese hospital: an underrecognized problem in Asia?","volume":"51","author":"Hawkey","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/gastro\/got029","article-title":"Overview of Clostridium difficile infection: implications for China","volume":"1","author":"Chen","year":"2013","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.jmii.2017.06.007_bib9","doi-asserted-by":"crossref","first-page":"18834","DOI":"10.1038\/srep18834","article-title":"The first two Clostridium difficile ribotype 027\/ST1 isolates identified in Beijing, China-an emerging problem or a Neglected threat?","volume":"6","author":"Cheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2017.06.007_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1473-3099(05)70215-2","article-title":"Treatment of Clostridium difficile-associated disease: old therapies and new strategies","volume":"5","author":"Aslam","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib11","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1086\/657116","article-title":"Management of Clostridium difficile infection: thinking inside and outside the box","volume":"51","author":"Gerding","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib12","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/cid\/cir830","article-title":"Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection","volume":"54","author":"Venugopal","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1592\/phco.31.9.877","article-title":"Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection","volume":"31","author":"Hardesty","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jmii.2017.06.007_bib15","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dku261","article-title":"Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison","volume":"69","author":"Cornely","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2017.06.007_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0144604","article-title":"The role of glutamate dehydrogenase (GDH) testing Assay in the diagnosis of Clostridium difficile infections: a high sensitive screening test and an essential step in the proposed laboratory diagnosis workflow for developing countries like China","volume":"10","author":"Cheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jmii.2017.06.007_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1099\/jmm.0.47714-0","article-title":"Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping","volume":"57","author":"Indra","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/JCM.01796-09","article-title":"Multilocus sequence typing of Clostridium difficile","volume":"48","author":"Griffiths","year":"2010","journal-title":"J Clin Microbiol"},{"year":"2012","series-title":"Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard-eighth edition, M11\u2013A8","author":"CLSI","key":"10.1016\/j.jmii.2017.06.007_bib19"},{"year":"2016","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement, M100\u2013S26","author":"CLSI","key":"10.1016\/j.jmii.2017.06.007_bib20"},{"year":"2016","series-title":"Breakpoint tables for interpretation of MICs and zone diameters, v6.0. 2016","author":"EUCAST","key":"10.1016\/j.jmii.2017.06.007_bib21"},{"key":"10.1016\/j.jmii.2017.06.007_bib22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijantimicag.2008.09.022","article-title":"Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes","volume":"33","author":"Huang","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2017.06.007_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in Adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1099\/jmm.0.45753-0","article-title":"Alternative treatments for Clostridium difficile disease: what really works?","volume":"54","author":"Mcfarland","year":"2005","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jmii.2017.06.007_bib25","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","article-title":"Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial","volume":"12","author":"Cornely","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2017.06.007_bib27","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/AAC.00845-15","article-title":"U.S.-Based national sentinel surveillance study for the epidemiology of Clostridium difficile-Associated diarrheal isolates and their susceptibility to fidaxomicin","volume":"59","author":"Snydman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2017.06.007_bib28","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/AAC.01136-13","article-title":"Comparative in\u00a0vitro Activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative Aerobic and anaerobic intestinal flora isolates","volume":"57","author":"Goldstein","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2017.06.007_bib29","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.cmi.2014.09.017","article-title":"Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes","volume":"21","author":"Freeman","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2017.06.007_bib30","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1093\/jac\/dkv092","article-title":"In\u00a0vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain","volume":"70","author":"Reigadas","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2017.06.007_bib31","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1128\/AAC.00191-12","article-title":"Characterizations of Clinical Isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan","volume":"56","author":"Liao","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2017.06.007_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.anaerobe.2014.08.002","article-title":"Investigation of the MICs of fidaxomicin and other antibiotics against Hungarian Clostridium difficile isolates","volume":"31","author":"Eitel","year":"2015","journal-title":"Anaerobe"},{"key":"10.1016\/j.jmii.2017.06.007_bib33","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.anaerobe.2014.07.001","article-title":"In\u00a0vitro activity of MCB3681 against Clostridium difficile strains","volume":"28","author":"Rashid","year":"2014","journal-title":"Anaerobe"},{"key":"10.1016\/j.jmii.2017.06.007_bib34","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/599224","article-title":"Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection","volume":"48","author":"Herpers","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.jmii.2017.06.007_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12418","article-title":"European Society of Clinical M, Infectious D. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection","volume":"20","author":"Debast","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jmii.2017.06.007_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s10096-014-2290-9","article-title":"Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Japan","volume":"34","author":"Kuwata","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1471-2334-12-109","article-title":"Clinical and microbiologic characteristics of tcdA negative variant Clostridium difficile infections","volume":"12","author":"Jieun","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2017.06.007_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijantimicag.2012.08.011","article-title":"Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital","volume":"41","author":"Dong","year":"2013","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118217301202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118217301202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:23:02Z","timestamp":1761657782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118217301202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1684118217301202"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2017.06.007","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High in\u00a0vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2017.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}